Health Care [ 10/12 ] | Biotechnology [ 44/73 ]
NASDAQ | Common Stock
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.
It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair.
Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 25 | -0.51 Increased by +50.49% | -0.54 Increased by +5.56% |
| May 5, 25 | -0.80 Increased by +26.61% | -0.92 Increased by +12.78% |
| Mar 31, 25 | -0.81 Increased by +17.35% | -0.91 Increased by +11.18% |
| Oct 29, 24 | -0.91 Decreased by -13.75% | -0.94 Increased by +3.19% |
| Jul 31, 24 | -1.03 Decreased by -47.14% | -1.07 Increased by +3.74% |
| May 2, 24 | -1.09 Decreased by -11.22% | -0.99 Decreased by -10.10% |
| Jan 9, 24 | -0.98 Decreased by -13.95% | -0.85 Decreased by -15.29% |
| Oct 30, 23 | -0.80 Decreased by -2.56% | -0.82 Increased by +2.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -20.74 M Increased by +44.36% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -29.26 M Increased by +25.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.22 M Decreased by -80.14% | -29.30 M Increased by +16.00% | Decreased by -2.40 K% Decreased by -322.88% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -32.79 M Decreased by -15.33% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -37.28 M Decreased by -49.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -39.06 M Decreased by -34.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 6.14 M Increased by +N/A% | -34.88 M Decreased by -44.73% | Decreased by -567.96% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -28.43 M Decreased by -27.51% | Decreased by N/A% Decreased by N/A% |